Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Epoetin Clear all
Terminated Phase 3 Interventional

Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy

NCT00083434
View directory record Official record
Conditions
Anemia, Cancer
Interventions
Epoetin alfa
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
6
States / cities
Anaheim, California • Arcadia, California • Fresno, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

NCT00364832
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
6
States / cities
Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Not applicable Interventional

Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation

NCT00355407
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Darbepoetin alfa
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2009 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

A Safety Study of Pentoxifylline for the Treatment of Anemia

NCT01102218
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Erythropoietin, Pentoxifylline
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2012 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial

NCT02564796
View directory record Official record
Conditions
Cyanotic Congenital Heart Disease, Anemia, Cyanosis, Congenital Heart Disease
Interventions
Epoetin Alfa and Iron, Iron
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 8 Weeks
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 30, 2026, 2:39 PM EDT
Withdrawn Not applicable Interventional

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

NCT00954486
View directory record Official record
Conditions
Anemia
Interventions
Epoetin alfa
Drug
Lead sponsor
Stanford University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Palo Alto, California • Stanford, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 30, 2026, 2:39 PM EDT
Completed No phase listed Observational

Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery

NCT01393418
View directory record Official record
Conditions
Erythropoietin, Acute Kidney Injury, Renal Biomarker
Interventions
Cardiac Surgery
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

NCT00454246
View directory record Official record
Conditions
Anemia
Interventions
methoxy polyethylene glycol-epoetin beta, epoetin alfa, darbepoetin alfa
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2011 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis

NCT01587898
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Azusa, California • Bakersfield, California • Chino, California + 38 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 4 Interventional

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

NCT00425126
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Epoetin Alfa
Drug
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 27, 2010 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 3 Interventional Results available

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

NCT00858364
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Anemia, Cancer, Lung Cancer
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
277
States / cities
Anniston, Alabama • Birmingham, Alabama • Anchorage, Alaska + 243 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Not applicable Interventional Results available

Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients

NCT01876732
View directory record Official record
Conditions
Vitamin B12 Deficiency
Interventions
Vitamin B12
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 90 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Not applicable Interventional Results available

Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose

NCT01263028
View directory record Official record
Conditions
Chronic Kidney Disease Stages 3-5
Interventions
Ergocalciferol supplementation
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 4 Interventional Results available

Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis

NCT01737879
View directory record Official record
Conditions
Anemia
Interventions
Peginesatide, Epoetin alfa
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Phoenix, Arizona • Tempe, Arizona • Azusa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Not applicable Interventional Results available

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

NCT00258440
View directory record Official record
Conditions
Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Weekly procrit dosing, Interval Dosing
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants

NCT02052310
View directory record Official record
Conditions
Anemia in Incident Dialysis Patients
Interventions
Roxadustat, Epoetin Alfa
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
1,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
30
States / cities
Chula Vista, California • La Mesa, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

NCT01693029
View directory record Official record
Conditions
Anemia, Chronic Kidney Disease (CKD)
Interventions
HX575 epoetin alfa, US-licensed epoetin alfa
Drug
Lead sponsor
Sandoz
Industry
Eligibility
18 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
52
States / cities
Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects

NCT03398473
View directory record Official record
Conditions
Healthy
Interventions
Epoetin Hospira SDV, Epoetin Hospira MDV
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

NCT00442416
View directory record Official record
Conditions
Anemia
Interventions
Epoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • Chula Vista, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2016 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

Mechanisms of EPO-induced Hypertension

NCT03810911
View directory record Official record
Conditions
Chronic Kidney Disease, Blood Pressure, Anemia
Interventions
Darbepoetin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 30, 2026, 2:39 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden

NCT03263091
View directory record Official record
Conditions
Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts), Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
30
States / cities
Bakersfield, California • Beverly Hills, California • Burbank, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 30, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

NCT00378352
View directory record Official record
Conditions
Acute ST Elevation Myocardial Infarction
Interventions
Epoetin alfa
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Washington D.C., District of Columbia • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 30, 2026, 2:39 PM EDT